IMBiologic’s technology and know-how for the bispecific antibody development enable the discovery of drug candidates with improved potency and manufacturability. By fusing two fully human monoclonal antibody fragments that recognize different antigens, our bispecific antibodies can simultaneously bind to two antigens with high specificity and balanced affinity.

We are leveraging the bispecific antibodies to implement a novel mode of action that offers distinguished advantages over monospecific antibodies.
- Recruiting immune cells to engage with the target cells
- Balancing between the inhibitory and activation signals simultaneously
- Promoting the association of two different antigens for a new treatment MoA